Skip to main content

ADVERTISEMENT

Emanuele Zucca, MD

Emanuele Zucca, MD
Conference Coverage
12/20/2023
At the 65th ASH Annual Meeting, Emanuele Zucca, MD, discussed long-term results from an updated analysis of the SAKK 35/10 trial, which indicated that rituximab plus lenalidomide therapy demonstrated durable efficacy among patients with...
At the 65th ASH Annual Meeting, Emanuele Zucca, MD, discussed long-term results from an updated analysis of the SAKK 35/10 trial, which indicated that rituximab plus lenalidomide therapy demonstrated durable efficacy among patients with...
At the 65th ASH Annual Meeting,...
12/20/2023
Oncology